Commercial strategy for Gilead's Covid-19 drug-to-be remdesivir remains opaque, as chief O'Day emphasizes responsibility
In his opening remarks on Thursday, Gilead chief Daniel O’Day did us all a favor, truncating his commentary on the quarter gone by to set aside more time to discuss in detail remdesivir: the compound at the heart of efforts to combat Covid-19.
But the big question remained — does Gilead plan to generate a return on its investment in the drug? O’Day did not answer that question directly, instead, he emphasized the need for responsibility.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.